Home › Cancro del polmone non a piccole cellule › Indiana › Indianapolis
Studi clinici su Cancro del polmone non a piccole cellule a Indianapolis, IN
32 studi su Cancro del polmone non a piccole cellule cercano partecipanti presso sedi a Indianapolis e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
In reclutamentoFase 3
- Saint Catherine Hospital, Indianapolis
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
In reclutamentoFase 3
- Saint Catherine Hospital, Indianapolis
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
In reclutamentoFase 1
- IU Simon Cancer Center, Indianapolis
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
In reclutamentoFase 3
- Franciscan Health ( Site 0219), Indianapolis
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
In reclutamentoFase 1
- Exelixis Clinical Site #4, Indianapolis
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
In reclutamentoFase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- IU Health West Hospital, Avon · a 13 mi di distanza
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
In reclutamentoFase 1
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
In reclutamentoFase 3
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
In reclutamentoFase 3
- Franciscan Health, Indianapolis
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
In reclutamentoFase 2/3
- Indiana University Health University Hospital, Indianapolis
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
In reclutamentoFase 1/2
- Indiana University (IU) Health - Multi-D Oncology Clinic, Indianapolis
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
In reclutamentoFase 1/2
- Community Health Network, Indianapolis
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
In reclutamentoFase 3
- Clinical Study Site, Indianapolis
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
In reclutamentoFase 2
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
In reclutamentoFase 3
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
- Community Cancer Center North, Indianapolis
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
In reclutamentoFase 1
- Community Health Network, Indianapolis
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
In reclutamentoFase 1
- Community Health Network, Indianapolis
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
In reclutamentoFase 1
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network Investigational Drug Services, Indianapolis
- e altri 1
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
In reclutamentoFase 3
- Franciscan Health Indianapolis, Indianapolis
A Study of LY4175408 in Participants With Advanced Cancer
In reclutamentoFase 1
- Community Health Network, Indianapolis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
In reclutamentoFase 1
- Community Health Network, Inc. /ID# 243011, Indianapolis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2/3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
In reclutamentoFase 2
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
A Study of VET3-TGI in Patients With Solid Tumors
In reclutamentoFase 1
- Community Health Network, Indianapolis
Repositioning Immunotherapy in VetArans With Lung Cancer
In reclutamentoFase 2
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
In reclutamentoFase 1/2
- Research Site, Indianapolis
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
In reclutamento
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
GEMINI-NSCLC: NSCLC Biomarker Study
In reclutamentoStudio osservazionale
- Community Health Network, Indianapolis
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
In reclutamento
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
In reclutamentoFase 1/2
- Community Health Network, Inc., Indianapolis
Studi su Cancro del polmone non a piccole cellule in altre città
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
Altri studi a Indianapolis
- Cancro (tutti i tipi)24 studi
- Insufficienza cardiaca23 studi
- Obesità20 studi
- Cancro al seno20 studi
- Cancro metastatico19 studi
- Cancro colorettale18 studi
- Cancro ovarico17 studi
- Malattie cardiovascolari17 studi
- Cancro ai polmoni16 studi
- Diabete di tipo 114 studi
- Cancro dell'endometrio14 studi
- Morbo di Alzheimer14 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.